- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02213653
Randomized Study Evaluating Agents Stimulants Erythropoiesis (ASE) Associated With Ferric Carboxymaltose (Ferinject ®) in Concomitant or Sequential Patients Treated for Cancer and With Anemia Associated With Functional Iron Deficiency
Phase IV Randomized Study Evaluating Agents Stimulants Erythropoiesis (ASE) Associated With Ferric Carboxymaltose (Ferinject ®) in Concomitant or Sequential Patients Treated for Cancer and With Anemia Associated With Functional Iron Deficiency
Anemia in patients with cancer is a common problem associated with an impaired quality of life.
Treatment with erythropoiesis stimulating agents (ESA) allows an increase in hemoglobin levels in 40-70% of patients and decreased transfusion requirements.
Absolute or functional iron deficiency is also common with about 30% of cancer patients with all histologies combined iron deficiency and anemia.
Several studies have shown the benefits of the combination of intravenous iron to erythropoiesis-stimulating agents in improving hemoglobin. However, none of them, to the investigators knowledge, has not been specifically performed on a population of patients with functional iron deficiency.
In addition, in clinical practice, this association is not carried out in particular because there is no dosage or consensus sequence for the administration of iron associated with ESAs.
Study Overview
Status
Conditions
Detailed Description
- Iron Deficiency and Cancer The literature review therefore presents uncertainties do not allow the routine application of intravenous iron associated with ESAs. The SOR also conclude that IV iron is "consider" if iron deficiency.
These uncertainties are the heterogeneity of the study populations, contradictory results and the use of patterns intravenous iron binding and non-standardized.
The investigators focus in this study in patients with chemotherapy-induced anemia with functional iron deficiency is a cause of lack of response to ESA. Indeed, patients with true iron deficiency seems to justify a routine iron supplementation. In contrast, patients without iron deficiency do not warrant formal way of initiating such treatment (although the literature is contradictory).
This study aims to evaluate, in patients with chemotherapy-induced anemia and functional iron deficiency, the efficacy and safety of the combination epoietin zeta + Iron in concomitant intravenous or sequential.
Because data RCP (Summary of Product Characteristics), ease of use, its safety profile, the ability to achieve higher doses of iron with a lower frequency and with better adherence, the ferric carboxymaltose was chosen as an intravenous iron. One specialty is available, the Ferinject ® (Laboratoires VIFOR Pharma).
The erythropoiesis-stimulating agent chosen in this study is epoietin zeta.
- Hepcidin and iron Hepcidin is a peptide hormone of 25 amino acids produced by the liver and considered as the central regulator of iron homeostasis in the body.
It works by controlling intestinal iron absorption and iron reuse by the reticuloendothelial system. Hepcidin acts by preventing the export of iron enterocytes, intestinal site of absorption of dietary iron, and macrophages, iron recycling site of hemoglobin, by binding to ferroportin present at the membrane these cells and by inducing its internalization and degradation.
Accordingly, hepcidin can be considered a hyposidérémiante hormone. The hepcidin rate is increased by the iron thereby limiting its accumulation and tissue damage associated with iron overload. Inversely, the rate is reduced hepcidin during increased iron as anemia needs, hypoxia, pregnancy or other situations of iron deficiency.
Moreover, hepcidin is strongly induced by inflammation. Thus, in pathological situations such as cancer, high levels of hepcidin explain well enough inflammatory anemia characterized by anemia, iron retention at storage proteins such as ferritin but also at the level of the reticuloendothelial system endothelial and a decrease in intestinal iron absorption.
Despite its importance in the pathophysiology of anemia of inflammation and a fortiori with iron deficiency anemia functional hepcidin is not measured in clinical routine. There is not, to the investigators knowledge, prospective data on its blood levels in situations of iron deficiency anemia in cancer patients functional and data on changes in hepcidin levels induced by treatment with intravenous iron or with erythropoietin.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Caen, France, 14076
- Centre Francois Baclesse
-
Caen, France, 14000
- CHU
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient> 18 years;
- Metastatic or locally advanced non-curable undergoing chemotherapy or lymphoid disease for which chemotherapy is indicated solid cancerous disease;
- Patient for which there are at least 3 cycles or 3 months of chemotherapy;
- Haemoglobin between 8.5 and 11 g / dL;
- Functional martial deficiency defined by a coefficient of transferrin saturation and serum ferritin ≤ 20% between 100 and 800 mg / L;
- Life expectancy> 3 months;
- ECOG ≤ 2.
Exclusion Criteria:
- Documented hemochromatosis ;
- AST and / or ALT> 2.5N;
- Renal impairment with Cockcroft clearance <30 mL / min;
- Vitamin B12 deficiency or folate;
- Hemolysis;
- Infectious disease being untreated;
- Haemorrhagic syndrome related or not with the tumor;
- Hypersensitivity to Ferinject ® or any of the excipients;
- Land atopic asthma or eczema known
- Contraindication to EPO;
- Taking a supplement to oral iron;
- Treatment with EPO within 6 months prior to study entry;
- No transfusion of packed red cells within 15 days before enrollment or randomization in the study;
- Participation in another clinical trial;
- Psychiatric pathology can disrupt the course of treatment or prevent the interpretation of results;
- Pregnant or lactating women;
- Persons deprived of liberty;
- Major subject to a measure of legal protection or unable to consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Concomitant iron and I.V. epoietin zeta
|
|
Experimental: Iron and I.V. epoietin zeta sequential
|
|
Active Comparator: Epoietin zeta
|
Epoietin zeta at a dose of 450 IU / kg per week subcutaneously begun in week 1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with hematopoietic response at 10 weeks.
Time Frame: The rate of hematopoietic response will be evaluated 10 weeks
|
The primary objective is to evaluate the rate of hematopoietic response to 10 weeks in patients with anemia and functional iron deficiency treated epoietin zeta + carboxymaltose concomitant IV iron, by epoietin zeta + carboxymaltose IV ferric sequential or epoietin zeta alone
|
The rate of hematopoietic response will be evaluated 10 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of transfusion requirements
Time Frame: The number of transfusions will be evaluated weekly Week 1-16
|
The secondary objective is to assess transfusion requirements will be evaluated throughout the study
|
The number of transfusions will be evaluated weekly Week 1-16
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The hematopoietic response at 6 and 16 weeks
Time Frame: The hematopoietic response will be evaluated at 6 and 16 weeks
|
The hematopoietic response will be evaluated at 6 and 16 weeks
|
|
The time to achieve the therapeutic goal (hemoglobin> 12g/dl or increase in hemoglobin> 2g/dl)
Time Frame: The time to achieve the therapeutic goal will be determine 6,10 and 16 weeks after treatment start
|
The time to achieve the therapeutic goal will be determine 6,10 and 16 weeks after treatment start
|
|
Quality of life
Time Frame: Quality of life will be evaluated 6,10 and 16 weeks after treatment start
|
Quality of life will be evaluated 6,10 and 16 weeks after treatment start
|
|
The consumption of erythropoiesis stimulating agent
Time Frame: The consumption of erythropoiesis stimulating agent will be evaluated 6,10 and 16 weeks after treatment start
|
The consumption of erythropoiesis stimulating agent will be evaluated 6,10 and 16 weeks after treatment start
|
|
The mean increase in hemoglobin concentration
Time Frame: The mean increase in hemoglobin concentration will be evaluated weekly Week 1-16
|
The mean increase in hemoglobin concentration will be evaluated weekly Week 1-16
|
|
The evolution of the iron status parameters
Time Frame: The evolution of the iron status parameters will be performed at weeks 4,6,10,13 and 16
|
Ferritin, CST, soluble transferrin receptor, reticulocytes, CRP will be dosed at weeks 4,6,10,13 and 16
|
The evolution of the iron status parameters will be performed at weeks 4,6,10,13 and 16
|
Tolerance
Time Frame: Tolerance will be evaluated at weeks 6, 10 and 16
|
Tolerance will be evaluated at weeks 6, 10 and 16
|
|
Fatigue
Time Frame: Fatigue will be evaluated 6,10 and 16 weeks after treatment start
|
Fatigue will be estimated with the generic scale FACT-G
|
Fatigue will be evaluated 6,10 and 16 weeks after treatment start
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Emmanuel SEVIN, MD, Centre Francois Baclesse
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FERASE
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Cancer Metastatic Disease
-
Albert Einstein College of MedicineTerminatedCancer | Solid Tumor | Metastatic Solid Tumor | Metastatic dMMR Solid CancerUnited States
-
Memorial Sloan Kettering Cancer CenterAstraZenecaRecruitingSolid Tumor | Metastatic Cancer | Metastatic Solid Tumor | Solid Tumor, Adult | Solid Carcinoma | Metastatic TumorUnited States
-
Institut CurieRecruitingMetastatic Solid Tumor CancerFrance
-
Daiichi Sankyo Co., Ltd.RecruitingSolid Tumor | Metastatic Solid Tumor | Advanced CancerJapan, United States, Canada
-
Sairopa B.V.RecruitingMetastatic Solid Tumor | Solid Tumor, Adult | Refractory CancerUnited States, Moldova, Republic of
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
CanWell Pharma Inc.RecruitingSolid Tumor | Cancer MetastaticUnited States
-
Kiromic, Inc.WithdrawnCancer | Metastatic Solid Malignancies
-
Nektar TherapeuticsCompletedAdvanced Cancer | Metastatic Solid TumorsUnited States
-
Aadi Bioscience, Inc.RecruitingMalignant Solid Neoplasm | Neoplasms | Cancer | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Metastasis | Advanced Solid Tumor | Metastatic Solid Tumor | Advanced Cancer | Tumor | Malignant Neoplasm | Malignant Tumor | Tumors | Cancer Metastatic | Tumor, Solid | Malignant Solid Tumor | TSC | TSC1 | TSC2 | Metastatic NeoplasmKorea, Republic of, United States, Puerto Rico
Clinical Trials on ARM A : IV iron + epoietin zeta
-
PfizerHospira, now a wholly owned subsidiary of PfizerCompletedChronic Kidney Disease (CKD)United States, Puerto Rico
-
University of Texas Southwestern Medical CenterTerminated
-
Hospital de Clinicas de Porto AlegreUnknownHeart Failure | AnemiaBrazil
-
Korea University Anam HospitalCompletedDiabetes MellitusKorea, Republic of
-
INSYS Therapeutics IncCompleted
-
Instituto Nacional de Cancer, BrazilEli Lilly and CompanyCompletedNon Small Cell Lung CarcinomaBrazil, United States
-
Hoffmann-La RocheActive, not recruitingInflammatory Breast Cancer | Early Breast Cancer | Locally Advanced Breast CancerCanada, Croatia, Spain, Argentina, Mexico, Korea, Republic of, Bosnia and Herzegovina, Brazil, Costa Rica, Turkey, Singapore, Bulgaria, South Africa, India, Peru, Kenya, Chile